subrosa Health & Capital AG: Building Launch Outcomes for Rare Disease and Biotech Innovators

subrosa Health & Capital AG has been named Best Management Consulting Business of the Year 2026 – United States in the Global 100 - 2026 awards. The recognition reflects an approach that aims to solve a persistent problem in life sciences: promising therapies can stall not because of science, but because the pieces required for launch are fragmented across vendors, advisers and internal teams.

subrosa’s message is direct: rare disease and biotech innovators need one partner that can connect patients, markets, teams and capital—from first data to first patients on therapy. Rather than selling a single function or a slide deck, the firm positions itself around the outcome: executing the work that drives real-world access and adoption.

A different model: strategy and execution under one roof

Across pharma, biotech and medtech, leaders often assemble a patchwork of providers—consultancies for strategy, recruiters for key hires, agencies for field execution, and financial advisers for funding or partnerships. subrosa argues that this fragmentation introduces delays and hand-off risk, especially in rare disease where timelines, access pathways and patient identification are uniquely challenging.

The firm’s “new thinking” centers on running the three areas that most influence launch success inside one company:

• Data that helps find and understand patients
• Teams that execute medical and commercial plans
• Capital that funds scale, partnerships and growth

In practice, this integrated model is designed to help innovators fill gaps quickly—whether the missing piece is a market entry plan, an enrolled trial, a medical field team, or the leadership talent to drive a global program.

What subrosa does: four focus areas for end-to-end launch

subrosa describes its work through four focus areas that align to common inflection points in biotech and rare disease programs:

Startups & Launch

Strategy and execution support for first global launches, with an emphasis on building board-ready plans and standing up real-world capabilities at speed.

Rare Disease

Support from clinic to early access to launch to patient—reflecting the long arc from early identification through sustained therapy adoption.

Patient Recruitment

Patient identification designed to happen earlier than standard approaches, helping reduce risk in clinical programs and speed the path to treatment.

Executive Search

Hiring leaders and teams who can execute at launch speed, especially when scaling from scientific innovation to commercial and medical operations.

One partner, seven solutions: built for modern life sciences complexity

To deliver against those focus areas, subrosa outlines seven solution categories spanning strategy, operations and resourcing. For growing life sciences companies, the appeal is simple: reduce the friction between planning and doing.

Go-to-Market Strategies

Board-ready launch planning, including sequencing decisions, health technology assessment considerations, pricing work and P&L thinking—elements that directly affect access and long-term value.

Patient Access

Finding patients, supporting treatment initiation and helping keep patients on therapy across markets—an especially critical challenge in rare disease where diagnosis can be delayed and care pathways vary widely.

Preclinical & Clinical Operations

Trial design and trial fill support with a focus on de-risking enrolment—often a major driver of timeline and cost in development programs.

Medical Solutions

Turning approvals into adoption by deploying medical teams that can support education and appropriate use in the field.

Commercial Engagements

Field, remote and omnichannel teams designed to sell and support in line with the customer journey and market realities.

Licensing, Funds & M&A

Support for capital raising, partnering and value realization—helping innovators connect strategy to financing and transaction readiness.

Talent & HR Services

Executive hiring and full team build-outs to match launch timelines, with an emphasis on speed without sacrificing fit.

Milestones that signal scale—and repeat trust

A key indicator for any consultancy is whether it can perform repeatedly across clients and contexts. subrosa reports several performance milestones that highlight reach across rare disease and biotech engagements:

• 58k+ rare disease patients recruited
• 600k+ patient genomes supported through its work
• 2,800+ executive placements
• 96% returning clients

For prospective clients, the returning-client metric is particularly meaningful: it suggests that once companies experience integrated delivery—spanning strategy, talent and execution—they come back when the next launch milestone arrives.

Why this matters now for pharma, biotech and medtech leaders

Life sciences is moving fast, but the operating environment is not getting simpler. Patient populations can be hard to identify, access pathways are complex, and global launches require synchronized medical, commercial and operational readiness. At the same time, teams are expected to do more with leaner structures—often while preparing for investment, partnering or a first commercial build.

subrosa’s positioning speaks to these pressures. Instead of asking innovators to coordinate multiple vendors and manage handovers, the firm aims to operate as a senior-led partner that can move from blueprint to build—linking patient data and recruitment with launch execution, and matching the plan with the people and capital required to deliver it.

Global 100 - 2026 recognition

Being awarded Best Management Consulting Business of the Year 2026 – United States underscores subrosa’s outcome-driven model in a crowded advisory market. The win reflects a proposition centered on real patient impact: aligning the work that finds patients, equips teams and funds growth—so innovators can move from first data to first patients on therapy with fewer gaps.

Contact details

Website: subrosa.health